Industry news that matters to you.  Learn more

Biomarker Briefs: July 25, 2011

Biomarker Briefs is an occasionally recurring series highlighting particularly interesting articles on biomarkers and/or personalized medicine.

George Washington University Researchers Receive NCI Award to Study Cancer from a Neglected Tropical Disease

Researchers from The George Washington University School of Medicine and Health Sciences (SMHS) have been awarded a five-year, $500,000-per-year R01 grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This award will support investigations by SMHS researchers who are developing proteomic biomarkers for Opisthorchis-induced bile duct cancer. The liver fluke Opisthorchis viverrini is a food-borne parasite that currently infects more than 40 million people, primarily in the Southeast Asian countries of Thailand, Laos, and Cambodia, where uncooked fish, intermediate hosts for O. viverrini, are a staple of the diet. O. viverrini is considered among the most important of the food-borne trematodes due to its strong association with bile duct fibrosis and bile duct cancer (cholangiocarcinoma) as determined by the World Health Organization’s International Agency for Research on Cancer (IARC). IARC categorizes this parasitic worm as a Group 1 carcinogen – a definitive cause of cancer.

Rules-Based Medicine Acquires Intellectual Property Assets of Satoris, Inc.

Rules-Based Medicine (RBM), a global leader in biomarker testing services, recently announced the acquisition of intellectual property assets from Satoris, Inc. The portfolio is based on extensive research to discover biomarkers and biomarker panels for clinical and research use in the areas of Alzheimer’s disease, frontal temporal dementia, Parkinson’s disease, and other conditions that affect the central nervous system.

SynapDx Corporation Licenses Autism Diagnostic Discoveries from Children’s Hospital Boston

SynapDx Corporation announced last week that it has obtained an exclusive world-wide license to technology from Children’s Hospital Boston to accelerate the Company’s development of blood-based tests to enable the early detection of Autism Spectrum Disorders. The discoveries were developed through collaboration by leading Children’s researchers, Dr. Louis Kunkel and Dr. Isaac Kohane. In 2010, SynapDx also obtained exclusive world-wide rights to blood-based autism detection technologies from George Washington University, based on the work of Dr. Valerie Hu.

Biomarker May Guide Decision for Dialysis Following Cardiac Surgery

According to the results of a multicenter study, interleukin 18 (IL18) reliably predicts the need for renal replacement therapy in patients who develop acute kidney injury after cardiac surgery.